ModeX Therapeutics, An OPKO Health Company
2 clinical trials · 2 recruiting · INDUSTRY
Trials by ModeX Therapeutics, An OPKO Health Company
RECRUITINGPhase 1 / Phase 2NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 1156 locations
Biliary Tract CancerBreast CancerCervical Cancer+13
RECRUITINGPhase 1NCT07445971
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by...
Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 802 locations
COVID -19COVID-19 (Prevention)